DTME0710

4Page 6 Media CME Using resorbable barriers to make root recession cover- age predictable 4Page 8 Practice Matters Dental Care or Beauty Treatment? 4Page 3 Trends & Applications A Challenging Task 2 Hours DENTAL TRIBUNE The World’s Dental Newspaper · Middle East & Africa Edition PUBLISHED IN DUBAI September 2010 NO. 7 VOL. 8 high quality glass ionomer cements first class composites innovative compomers modern bonding systems materials for long-term prophylaxis temporary solutions bleaching products… All our products convince by excellent physical properties perfect aesthetical results Highest quality made in Germany PROMEDICA Dental Material GmbH Tel. + 49 43 21 / 5 4173 · Fax + 49 43 21 / 519 08 Internet: http://www.promedica.de · eMail: info@promedica.de Temporary crown and bridge material New: Bleach Shade! Light-curing nano-ceram composite to the packable Composan bio-esthetic Nano-Ceram-Technology Meet us at several exhibitions – www.promedica.de AD WASHINGTON — The Food and Drug Administration is re- viewing data suggesting a pos- sible link between the widely used diabetes medication Ac- tos and bladder cancer. The agency said Friday that five-yearresultsfromanongoing study show that patients who have taken Actos for the longest periodoftimehadahigherriskof bladder cancer. Bladder cancer was also more prevalent in pa- tients who had taken the largest cumulative dose of the drug. Actos manufacturer Takeda Pharmaceuticals is conducting the study, which is scheduled to run 10 years. “The agency has not con- cluded that Actos increases the risk of bladder cancer,” the agency said in a statement. Pa- tients should continue taking Ac- tos unless told otherwise by their doctor, according to the agency statement. Actos agreed to study the risk of bladder cancer with its drug in 2003. But a company executive said Friday the results are too preliminary to make any conclu- sions about the drug. “This interim analysis raises a question, but it doesn’t answer anything,” said Dr. Robert Span- heimer, vice president of med- ical affairs at Takeda. “We are committed to finishing the study because I think that’s when you’re going to get the greater understanding.” Prescriptions for Actos have risen since 2007, when its chief competitor, Avandia, was first as- sociated with cardiovascular problems. The FDA is consider- ing whether to withdraw Avan- dia, which is marketed by British drugmaker GlaxoSmithKline. ActosandAvandiaworksimilarly tocontrolbloodsugarandarethe onlydrugsintheirclasscurrently onthemarket.Athirddrugcalled Rezulin was withdrawn in the U.S. in 1997 due to liver toxicity. Critics of Avandia have called on the FDA to recall the drug, ar- guing that Actos offers the same benefits without risks of heart at- tack and stroke. The FDA’s review of Actos’ cancer risks is preliminary, but could shape its decision on Avan- dia, which is expected in coming weeks. U.S sales of Actos have risen steadily - hitting $3.4 billion last year-asAvandia’sreputationhas soured. Last year Avandia posted $520 million in sales. DT Diabetes Pill Actos May Pose Cancer Risk FDA Reviewing Suggesting Possible Link More than 100,000 children left homeless by Pakistan's floods are in danger of dying because they simply do not have enough to eat, according to UNICEF. Children already weak from liv- ing on too little food in poor ru- ral areas before the floods are fighting to stay alive, as diar- rhea, respiratory diseases and malaria attack their emaciated bodies. Doctors roaming the 100-de- gree (38-degree Celsius) camp thatreeksofurineandanimalma- nure have warned Bunglani three times to take her children to the hospital, or they will die. The mother says she knows they need help, but she cannot Kids without food in Pakistan floods face death In this Sept. 13, 2010 photo, a Pak- istani mother helps her child drink water in Sukkur, Sindh province, southern Pakistan. (AP Photo/Aaron Favila) page 2DT

Please activate JavaScript!
Please install Adobe Flash Player, click here for download